Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
7.99
-0.31 (-3.68%)
Mar 31, 2025, 1:23 PM EDT - Market open
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aurinia Pharmaceuticals stock have an average target of 11.5, with a low estimate of 10 and a high estimate of 13. The average target predicts an increase of 44.02% from the current stock price of 7.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $10 | Buy | Reiterates | $10 | +25.23% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $10 | Buy | Reiterates | $10 | +25.23% | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +62.81% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +62.81% | Mar 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +25.23% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
263.03M
from 235.13M
Increased by 11.86%
Revenue Next Year
328.68M
from 263.03M
Increased by 24.96%
EPS This Year
0.45
from 0.04
Increased by 1,037.30%
EPS Next Year
0.77
from 0.45
Increased by 68.16%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 273.0M | 459.6M | 556.4M | ||
| Avg | 263.0M | 328.7M | 400.2M | ||
| Low | 250.7M | 284.2M | 313.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.1% | 74.7% | 69.3% | ||
| Avg | 11.9% | 25.0% | 21.7% | ||
| Low | 6.6% | 8.0% | -4.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.61 | 1.40 | 1.82 | ||
| Avg | 0.45 | 0.77 | 1.12 | ||
| Low | 0.33 | 0.44 | 0.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,422.5% | 207.0% | 137.5% | ||
| Avg | 1,037.3% | 68.2% | 46.2% | ||
| Low | 733.0% | -3.1% | -10.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.